Ashkon Software



CNDO - Coronado Biosciences, Inc.

CNDO Stock Chart

CNDO Profile

Coronado Biosciences, Inc. logo

Coronado Biosciences, Inc. (CNDO) is no longer a publicly traded company. As of my knowledge cutoff of September 2021, the company was acquired by a private company, and its stock is no longer listed on any major stock exchanges.

Coronado Biosciences was a clinical-stage biopharmaceutical company focused on the development of immunotherapy products for the treatment of autoimmune diseases and cancer. The company's lead product candidate was CNDO-109, a biologic therapy that was being developed for the treatment of autoimmune and inflammatory diseases such as Crohn's disease and ulcerative colitis.

CNDO-109 was designed to selectively deplete disease-causing immune cells while leaving healthy immune cells intact. The therapy used a unique combination of drugs to target and eliminate specific immune cells, potentially providing a more targeted and effective treatment option for patients with autoimmune and inflammatory diseases.

However, it appears that the development of CNDO-109 and other product candidates has been discontinued following the company's acquisition. As a result, there is no further information available about the current status of Coronado Biosciences or its product development


Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer